

David Sibon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6800430/publications.pdf>

Version: 2024-02-01

84
papers

2,334
citations

236925

25
h-index

233421

45
g-index

87
all docs

87
docs citations

87
times ranked

3575
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenetic landscape of lymphomagenesis in coeliac disease. <i>Gut</i> , 2022, 71, 497-508.	12.1	48
2	Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. <i>Annals of Hematology</i> , 2022, 101, 317-332.	1.8	2
3	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
4	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1091-1101.	1.6	11
5	De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells. <i>Molecular Cancer</i> , 2022, 21, 65.	19.2	0
6	Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. <i>Haematologica</i> , 2022, 107, 1681-1686.	3.5	12
7	Peripheral T-Cell Lymphomas: Therapeutic Approaches. <i>Cancers</i> , 2022, 14, 2332.	3.7	4
8	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. <i>Blood Advances</i> , 2022, 6, 6169-6179.	5.2	5
9	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021, 137, 2646-2656.	1.4	39
10	Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. <i>Leukemia</i> , 2021, 35, 764-776.	7.2	24
11	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	1.4	48
12	Vascular access for optimal hematopoietic stem cell collection. <i>Journal of Clinical Apheresis</i> , 2021, 36, 12-19.	1.3	9
13	Minimal Residual Disease Monitoring Using a β -ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 131-139.	2.8	12
14	Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011). <i>Journal of Clinical Oncology</i> , 2021, 39, 3251-3260.	1.6	17
15	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	4
16	Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa. <i>Annals of Hematology</i> , 2021, 100, 2813-2824.	1.8	11
17	Super-enhancer-based identification of a BATF3/IL-2R γ module reveals vulnerabilities in anaplastic large cell lymphoma. <i>Nature Communications</i> , 2021, 12, 5577.	12.8	21
18	Arsenic trioxide (As ₂ O ₃) as a maintenance therapy for adult T cell leukemia/lymphoma. <i>Retrovirology</i> , 2020, 17, 5.	2.0	20

#	ARTICLE	IF	CITATIONS
19	Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin. <i>Bone Marrow Transplantation</i> , 2020, 55, 1834-1836.	2.4	5
20	New drugs toxicity: incidence and management. <i>Hematologie</i> , 2020, 26, 43-46.	0.0	0
21	Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
22	Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial". <i>Blood</i> , 2020, 136, 15-16.	1.4	2
23	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. <i>Blood</i> , 2020, 136, 20-21.	1.4	3
24	Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. <i>Blood</i> , 2019, 134, 641-644.	1.4	77
25	Sinusoidal Obstruction Syndrome: Warning About Autologous Stem Cell Transplantation Preceded by Regimens Containing Oxaliplatin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S264-S265.	0.4	0
26	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 677-687.	1.6	162
27	Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study. <i>British Journal of Haematology</i> , 2019, 187, 65-72.	2.5	3
28	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , 2019, 104, e562-e565.	3.5	38
29	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. <i>Leukemia and Lymphoma</i> , 2019, 60, 2802-2805.	1.3	10
30	Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin. <i>Cell Reports</i> , 2019, 26, 3246-3256.e4.	6.4	15
31	The Need for a Consensus Next-Generation Sequencing Panel for Mature Lymphoid Malignancies. <i>HemaSphere</i> , 2019, 3, e169.	2.7	26
32	NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. <i>Gut</i> , 2019, 68, 1396-1405.	12.1	47
33	A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 111-122.	2.8	12
34	CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria. <i>Blood</i> , 2019, 134, 2887-2887.	1.4	3
35	Definition of a minimal genes set for mature lymphoid blood diseases. <i>Hematologie</i> , 2018, 24, 27-59.	0.0	4
36	New perspectives in the therapeutic approach of peripheral T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2018, 30, 285-291.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin. <i>Blood</i> , 2018, 132, 4597-4597.	1.4	1
38	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the Apre-brentuximab vedotin era: A LYSA/SFGM-TC study. <i>European Journal of Cancer</i> , 2017, 83, 146-153.	2.8	18
39	NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY. <i>Hematological Oncology</i> , 2017, 35, 44-45.	1.7	2
40	Pre-transplant donor CD4 ⁺ invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. <i>Leukemia</i> , 2017, 31, 903-912.	7.2	45
41	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. <i>Oncotarget</i> , 2016, 7, 85573-85583.	1.8	13
42	Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. <i>Haematologica</i> , 2016, 101, 474-481.	3.5	44
43	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.5	19
44	Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile. <i>Blood</i> , 2016, 128, 2962-2962.	1.4	0
45	Adult T-cell leukemia/lymphoma in a Caucasian patient after sexual transmission of HTLV-1. <i>Retrovirology</i> , 2015, 12, .	2.0	0
46	Adult T-Cell Leukemia/Lymphoma in a Caucasian Patient After Sexual Transmission of Human T-Cell Lymphotropic Virus Type 1. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv032.	0.9	11
47	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lympho study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	4.1	84
48	Enteropathy-Associated T-Cell Lymphoma: Improving Treatment Strategies. <i>Digestive Diseases</i> , 2015, 33, 231-235.	1.9	42
49	Autologous hematopoietic stem cell transplantation in elderly patients (>70years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 346-352.	1.0	31
50	Chromatin Redistribution of the DEK Oncoprotein Represses hTERT Transcription in Leukemias. <i>Neoplasia</i> , 2014, 16, 21-W14.	5.3	12
51	Mosaicism of HTLV-1 5' LTR CpG methylation in the absence of malignancy. <i>Virus Research</i> , 2013, 178, 452-461.	2.2	3
52	Therapeutic Options for Adult T-Cell Leukemia/Lymphoma. <i>Current Oncology Reports</i> , 2013, 15, 457-464.	4.0	38
53	Life without Peripheral Serotonin: Insights from Tryptophan Hydroxylase 1 Knockout Mice Reveal the Existence of Paracrine/Autocrine Serotonergic Networks. <i>ACS Chemical Neuroscience</i> , 2013, 4, 64-71.	3.5	127
54	Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 2430-2434.	1.2	89

#	ARTICLE	IF	CITATIONS
55	Autoimmune Hemolytic Anemia and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Rare Association. <i>Case Reports in Hematology</i> , 2013, 2013, 1-5.	0.4	3
56	Serotonin Is a Key Factor for Mouse Red Blood Cell Survival. <i>PLoS ONE</i> , 2013, 8, e83010.	2.5	29
57	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. <i>Blood</i> , 2013, 122, 3005-3005.	1.4	0
58	Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-8.	2.0	17
59	Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Étude des Lymphomes de l'Adulte Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 3939-3946.	1.6	162
60	HTLV-1 positive and negative T cells cloned from infected individuals display telomerase and telomere genes deregulation that predominate in activated but untransformed CD4+ T cells. <i>International Journal of Cancer</i> , 2012, 131, 821-833.	5.1	10
61	Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. <i>Blood</i> , 2012, 120, 2144-2154.	1.4	102
62	Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. <i>British Journal of Haematology</i> , 2012, 156, 619-625.	2.5	32
63	Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. <i>British Journal of Haematology</i> , 2011, 153, 191-198.	2.5	21
64	Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. <i>Experimental Hematology</i> , 2011, 39, 195-202.e2.	0.4	34
65	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1135-1143.	2.3	4
66	Two Atypical Cases of Cutaneous Gamma/Delta T-Cell Lymphomas. <i>Dermatology</i> , 2011, 222, 297-303.	2.1	23
67	Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience. <i>Blood</i> , 2011, 118, 2623-2623.	1.4	0
68	18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1095-1105.	6.4	129
69	Clonal expansion of HTLV-1 positive CD8+ cells relies on cIAP-2 but not on c-FLIP expression. <i>Virology</i> , 2010, 407, 341-351.	2.4	16
70	High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 2227-2232.	1.6	131
71	Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo. <i>Retrovirology</i> , 2010, 7, 17.	2.0	20
72	Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 262-269.	0.4	52

#	ARTICLE	IF	CITATIONS
73	New onset of myasthenia gravis after treatment of systemic sclerosis by autologous hematopoietic stem cell transplantation: Sustained autoimmunity or inadequate reset of tolerance?. Human Immunology, 2010, 71, 363-365.	2.4	8
74	Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL). Blood, 2010, 116, 2860-2860.	1.4	3
75	Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA). Blood, 2010, 116, 322-322.	1.4	6
76	Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2010, 116, 4002-4002.	1.4	0
77	Clonal expansion of HTLV-1 infected cells depends on the CD4 versus CD8 phenotype. Frontiers in Bioscience - Landmark, 2009, Volume, 3935.	3.0	21
78	Tax unleashed: Fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation. Journal of Clinical Virology, 2009, 46, 378-380.	3.1	1
79	Optimal treatment for relapsing patients with Hodgkin lymphoma. Expert Review of Hematology, 2009, 2, 285-295.	2.2	2
80	R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study.. Blood, 2009, 114, 406-406.	1.4	23
81	Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. Annals of Oncology, 2008, 19, 1915-1920.	1.2	8
82	Endemic versus epidemic viral spreads display distinct patterns of HTLV-2b replication. Virology, 2006, 345, 13-21.	2.4	7
83	HTLV-1 propels untransformed CD4+ lymphocytes into the cell cycle while protecting CD8+ cells from death. Journal of Clinical Investigation, 2006, 116, 974-983.	8.2	61
84	Fate of Premalignant Clones during the Asymptomatic Phase Preceding Lymphoid Malignancy. Cancer Research, 2005, 65, 1234-1243.	0.9	26